Skip to main content
Premium Trial:

Request an Annual Quote

CML HealthCare Licenses Rights to XDx's AlloMap

NEW YORK (GenomeWeb News) – CML HealthCare and XDx jointly announced today that CML has licensed exclusive rights to market XDx's AlloMap test initially in Ontario, Canada but with an option to extend the rights across the country.

Mississauga, Ontario-based CML, a publicly held diagnostic services provider, expects to begin offering the test later this summer. Financial and other terms of the alliance were not disclosed.

XDx's AlloMap measures the expression levels of a set of genes from a blood sample, providing clinicians a tool for evaluating a patient's risk for a heart transplant rejection. The company launched the test in 2005, and three years later the US Food and Drug Administration approved AlloMap.

The Brisbane, Calif.-based firm recently signed a memorandum of understanding that would provide an exclusive license to Diaxonhit for the AlloMap test in Europe. That deal would make Diaxonhit XDx's exclusive partner on the continent.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.